NERVGEN PHARMA CORP. (NGEN) Financial Statements
NERVGEN PHARMA CORP. (NGEN) files with the U.S. Securities and Exchange Commission under CIK 0001751912. 10KGenie shows its annual statements from SEC filings.
Key Figures, Fiscal Year 2025
- Net Income
- -44.12 million CAD
- Total Assets
- 23.21 million CAD
- Net Cash from Operations
- -19.50 million CAD
Fiscal year ended Dec 31, 2025. Latest periodic SEC filing: Mar 31, 2026. Source: SEC filings (EDGAR XBRL). Amounts in CAD.
Open the full financial statements for NGEN in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History